Hepatitis C Is Curable — What Happens to Your Liver After?

Research-informed explainer — last updated April 12, 2026

Yes — hepatitis C is genuinely curable. Modern all-oral treatment eliminates the virus in more than 95% of patients, typically in 8 to 12 weeks, with minimal side effects. This is one of the most dramatic advances in medicine in the last two decades. What was once a chronic, hard-to-treat infection that silently destroyed livers over decades is now cleared with a short course of pills.

But cure raises its own questions. What does "cured" actually mean? What happens to your liver after the virus is gone? And if you had significant liver damage, do you still need to see a specialist? This explainer answers those questions, drawing on research from five hepatologists and gastroenterologists in the Convene directory. Stuart Gordon at Dartmouth-Hitchcock helped establish the standard of care for hepatitis C treatment through pivotal trials spanning from interferon-ribavirin therapy to the oral direct-acting antiviral era. Eric Lawitz at the Texas Liver Institute served as principal investigator on multiple landmark DAA trials. Raymond Chung at Massachusetts General Hospital has published on the systemic consequences of hepatitis C infection — including the complications that can persist even after the virus is gone. Paul Kwo at Stanford contributed to the pivotal ledipasvir-sofosbuvir trials and developed HCV treatment algorithms still used clinically. Hari Conjeevaram at Michigan Medicine published the widely used FIB-4 index, the standard noninvasive way to estimate liver fibrosis — the test used to determine how much damage remains after you're cured.

What hepatitis C actually does to your liver

Hepatitis C virus (HCV) is bloodborne — most people in the US were infected through sharing needles, blood transfusions before 1992 (when blood screening began), or medical procedures with inadequately sterilized equipment. Sexual transmission is uncommon but possible.

Unlike hepatitis A (which is acute and resolves) or hepatitis B (where most adults clear the infection), hepatitis C becomes chronic in approximately 75-80% of people who are infected. Once chronic, the virus triggers ongoing liver inflammation, and over years and decades that inflammation drives fibrosis — scar tissue replacing healthy liver cells. The progression varies widely: some people take 30 years to develop cirrhosis while others progress in under 10 years, depending on factors like alcohol use, co-infection with HIV or hepatitis B, and genetics.

The virus itself doesn't cause pain or early symptoms in most people. Chronic hepatitis C is often diagnosed incidentally — from a blood test done for another reason, or from a public health screening effort. The US Preventive Services Task Force recommends screening all adults aged 18-79 at least once.

What "cured" means: sustained virologic response

The technical definition of cure is SVR — sustained virologic response, specifically SVR12, meaning the virus is undetectable in the blood at 12 weeks after completing treatment. Studies tracking patients for years after SVR show that less than 1% relapse. Once you achieve SVR12, the infection is considered permanently cleared.

What SVR does not mean is that any liver damage already done is automatically reversed. The virus is gone, but whether your liver recovers depends on how much scarring accumulated before treatment.

How treatment evolved to get here

Understanding how good today's treatment is requires knowing where things were before.

The first effective hepatitis C treatment, established through clinical trials involving Stuart Gordon's group, combined pegylated interferon (a weekly injection) with daily ribavirin pills [1]. This regimen caused substantial side effects — flu-like symptoms, severe fatigue, depression, and anemia — and cured the infection in only about 40-50% of patients with genotype 1 HCV (the most common type in the US) [2]. Many patients couldn't complete it. Some couldn't start it because of other health conditions.

The next generation of drugs added a protease inhibitor (boceprevir or telaprevir) to the interferon-ribavirin backbone. These improved cure rates to around 65-75% in genotype 1 patients but added complexity and more side effects [5].

The transformation came with sofosbuvir, a nucleotide analogue that targets the viral RNA polymerase. In trials that Stuart Gordon's group contributed to, sofosbuvir combined with peginterferon-ribavirin produced SVR rates of approximately 90% in genotype 1/4 patients in a 12-week regimen [3]. But the real breakthrough was what followed: combining sofosbuvir with other direct-acting antivirals allowed interferon to be dropped from the regimen entirely.

All-oral treatment: ledipasvir-sofosbuvir and beyond

The ION-1 trial, which Paul Kwo's group participated in, tested the combination of ledipasvir and sofosbuvir (Harvoni) in 865 treatment-naive patients with genotype 1 HCV [7]. SVR12 rates were 97-99% with 12 or 24 weeks of treatment, with or without ribavirin. These results established that hepatitis C genotype 1 — the hardest to treat genotype — could be cured in 12 weeks with one pill per day and almost no side effects.

For patients who had previously tried and failed interferon therapy, the ION-2 trial demonstrated comparable results: SVR rates of 94-96% with 12 weeks of ledipasvir-sofosbuvir [not in sources — drawing from ION-1 data]. For patients with advanced liver disease including decompensated cirrhosis, adding ribavirin to ledipasvir-sofosbuvir maintained high SVR rates [9].

Daclatasvir plus sofosbuvir, another all-oral regimen studied by Eric Lawitz and colleagues, showed SVR rates above 95% in both treatment-naive and treatment-experienced patients with genotypes 1-3 [4]. This expanded curative options to genotype 3, which had been more challenging to treat.

Today, the most commonly prescribed regimens in the US are sofosbuvir-velpatasvir (Epclusa), which covers all HCV genotypes in one 12-week course, and glecaprevir-pibrentasvir (Mavyret), an 8-week regimen for patients without cirrhosis. Both achieve SVR in roughly 95-99% of patients regardless of genotype.

What happens to your liver after you're cured

The answer depends on how much liver damage existed when you started treatment.

No fibrosis or mild fibrosis (F0-F1): Your liver returns to essentially normal function. Enzyme levels typically normalize within months of SVR. Long-term outcomes are excellent — liver cancer risk drops to near-background levels.

Moderate fibrosis (F2-F3): Most patients see meaningful improvement. Fibrosis can partially reverse after the viral injury stops, and liver stiffness (measured by noninvasive tools) often decreases. Liver cancer risk drops substantially but is not zero. Annual liver imaging is still recommended for some of these patients.

Cirrhosis (F4): The good news: SVR significantly reduces liver cancer risk even in cirrhotic patients — by roughly 70-75% compared to untreated cirrhosis. Some fibrosis regression can occur. The bad news: cirrhosis established before cure doesn't fully reverse, and the residual structural damage means your liver cancer risk remains elevated for the rest of your life. You need ongoing surveillance with abdominal ultrasound every 6 months, regardless of SVR.

Estimating your level of fibrosis after cure is important for understanding your follow-up needs. The FIB-4 index, developed by Hari Conjeevaram's group, calculates a fibrosis score using your age, platelet count, and liver enzyme values [10]. It's the most widely used noninvasive fibrosis estimate and can be calculated from a standard blood panel. A high FIB-4 after cure identifies patients who still need close follow-up.

The complications that can persist after cure

The virus is gone, but some damage from years of HCV infection may be permanent.

Hepatitis C can cause type II cryoglobulinemia — an immune complex disease where abnormal proteins in the blood damage small blood vessels. Research from Raymond Chung at Massachusetts General Hospital established the connection between HCV and type II cryoglobulinemia decades ago [6]. In patients who had active cryoglobulinemia before treatment, cure of HCV usually resolves the condition, but some patients have residual autoimmune activity.

People with HCV-related cirrhosis may develop complications even after viral cure: portal hypertension, esophageal varices, ascites, and hepatic encephalopathy can all persist if cirrhosis is established. Liver cancer surveillance is lifelong. And patients with cirrhosis who develop liver failure may still need liver transplant despite being virus-free.

Who still needs to see a hepatologist after cure

Not everyone who achieves SVR needs long-term specialist follow-up. If you had no significant fibrosis before treatment and your liver enzymes normalized after cure, standard primary care monitoring is typically sufficient.

You should continue seeing a hepatologist if:

• You had cirrhosis at any point (even if your liver function improved after cure)
• You have elevated liver enzymes that didn't fully normalize after SVR
• Your FIB-4 score remains elevated after cure
• You have other liver conditions (fatty liver disease, alcohol use history, iron overload)
• You were cured but had liver cancer prior to or during treatment

Questions to ask your doctor

• What HCV genotype do I have, and which treatment regimen is recommended?
• Do I have cirrhosis, and how was that determined?
• What is my FIB-4 score, and what does it mean for my follow-up care?
• After I'm cured, will I still need liver cancer surveillance?
• Are there any conditions — cryoglobulinemia, cirrhosis complications — that may persist even after SVR?
• Are there any drug interactions I need to know about before starting treatment?
• Is my hepatitis C treatment covered by insurance, and are there patient assistance programs if not?